公开(公告)号：US20230227405A1

公开(公告)日：2023-07-20

申请号：US18009310

申请日：2021-06-14

申请人： Ashok ARASAPPAN ,  Ian M. BELL ,  Jason M. COX ,  Michael J. KELLY, III ,  Mark E. LAYTON ,  Hong LIU ,  Jian LIU ,  Akshay A. SHAH ,  Michael D. VANHEYST ,  MERCK SHARP & DOHME CORP.

发明人： Ashok Arasappan ,  Ian M. Bell ,  Jason Michael Cox ,  Michael J. Kelly, III ,  Mark E. Layton ,  Hong Liu ,  Jian Liu ,  Akshay A. Shah ,  Michael David VanHeyst

IPC分类号： C07D207/277 ,  C07D401/12 ,  C07D417/12

CPC分类号： C07D207/277 ,  C07D401/12 ,  C07D417/12

摘要： Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

公开(公告)号：US20230227441A1

公开(公告)日：2023-07-20

申请号：US18009306

申请日：2021-06-14

申请人： Ashok ARASAPPAN ,  Ian M. BELL ,  Christopher James BUNGARD ,  Christopher S. BURGEY ,  Jason M. COX ,  Deodial Guy GUIADEEN ,  Michael J. KELLY ,  Mark E. LAYTON ,  Hong LIU ,  Jian LIU ,  James T. OLSEN ,  James J. PERKINS ,  Jeffrey W. SCHUBERT ,  Akshay A. SHAH ,  Michael D. VANHEYST ,  Zhe WU ,  Shawn J. STACHEL ,  MERCK SHARP & DOHME CORP.

发明人： Ashok Arasappan ,  Ian M. Bell ,  Christopher James Bungard ,  Christopher S. Burgey ,  Jason Michael Cox ,  Deodial Guy Guiadeen, III ,  Michael J. Kelly, III ,  Mark E. Layton ,  Hong Liu ,  Jian Liu ,  James T. Olsen ,  James J. Perkins ,  Jeffrey W. Schubert ,  Akshay A. Shah ,  Shawn J. Stachel ,  Michael David VanHeyst ,  Zhe Wu

IPC分类号： C07D413/12 ,  C07D263/24 ,  C07D417/12

CPC分类号： C07D413/12 ,  C07D263/24 ,  C07D417/12

摘要： Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

公开(公告)号：US11802122B2

公开(公告)日：2023-10-31

申请号：US17347639

申请日：2021-06-15

申请人： Merck Sharp & Dohme Corp.

发明人： Ashok Arasappan ,  Ian M. Bell ,  Christopher James Bungard ,  Christopher S. Burgey ,  Jason M. Cox ,  Michael J. Kelly, III ,  Mark E. Layton ,  Hong Liu ,  Jian Liu ,  James J. Perkins ,  Akshay A. Shah ,  Michael David VanHeyst ,  Zhe Wu

IPC分类号： C07D403/12 ,  C07D233/32 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D513/04 ,  A61K31/4166 ,  A61P25/00 ,  A61P25/04 ,  A61P29/00

CPC分类号： C07D403/12 ,  C07D233/32 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D513/04

摘要： Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

公开(公告)号：US20210403457A1

公开(公告)日：2021-12-30

申请号：US17347639

申请日：2021-06-15

申请人： Merck Sharp & Dohme Corp.

发明人： Ashok Arasappan ,  Ian M. Bell ,  Christopher James Bungard ,  Christopher S. Burgey ,  Jason M. Cox ,  Michael J. Kelly, III ,  Mark E. Layton ,  Hong Liu ,  Jian Liu ,  James J. Perkins ,  Akshay A. Shah ,  Michael David VanHeyst ,  Zhe Wu

IPC分类号： C07D403/12 ,  C07D233/32 ,  C07D401/14 ,  C07D401/12 ,  C07D405/12 ,  C07D417/12 ,  C07D417/14 ,  C07D413/12 ,  C07D513/04 ,  C07D471/08 ,  C07D471/04

摘要： Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.